Why the study?
Do acellular pertussis vaccines improve safety and immunogenicity compared to whole cell pertussis vaccines in infants?
Do acellular pertussis vaccines improve safety and immunogenicity compared to whole cell pertussis vaccines in infants?
Acellular pertussis vaccines are highly immunogenic and safer than whole cell pertussis vaccines in infants.
Supports preferring acellular pertussis vaccines for infant primary series; confirms superior safety with preserved immunogenicity versus whole-cell vaccines in RCT data.
A multicenter, randomized, double-blind study was undertaken in 2342 infants to evaluate the safety and immunogenicity of 13 acellular and 2 whole cell pertussis vaccines combined with diphtheria and tetanus toxoids. Vaccines were administered to infants at 2, 4, and 6 months of age. Sera were obtained before the first vaccination (age 2 months) and 1 month after the third vaccination (age 7 months). All of the acellular vaccines produced significant increases in antibody for included antigens; mean antibody levels often exceeded those obtained with the reference whole cell vaccine. The vaccines were well-tolerated. All acellular vaccines were associated with significantly fewer adverse reactions than the control whole cell vaccine.
No takes yet. Share an insight, caveat, or question.
Decker et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: